Apyx Medical (APYX)

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company's Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. Renuvion offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.

Company profile

Ticker

APYX

Exchange

NASDAQ

Website

apyxmedical.com

CEO

Robert Gershon

Incorporated

Delaware

Location

Florida

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...

Former names

AN CON GENETICS INC, BOVIE MEDICAL CORP, BOVIE MEDICAL Corp

SEC CIK

0000719135

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Apyx China Holding Corp. ...

IRS number

112644611

APYX stock data

1M 1Y 5Y

News

From Benzinga Pro

Lake Street Maintains Buy on Apyx Medical, Raises Price Target to $17

19 Jul 22

Lake Street analyst Kyle Bauser maintains Apyx Medical (NASDAQ:APYX) with a Buy and raises the price target from $14 to $17.

Recap of Monday's Biotech Catalysts - End of the Day Summary

18 Jul 22

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

Apyx Medical's Renuvion Scores FDA Approval To Eliminate Sagging Neck

18 Jul 22

Apyx Medical Corporation Receives FDA 510(k) Clearance For The Use Of Renuvion To Improve Appearance Of Lax Skin

18 Jul 22

Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin

11 Jul 22

Press releases

From Benzinga Pro

SHAREHOLDER ALERT: APYX MF CVNA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

5 Aug 22

NEW YORK, NY / ACCESSWIRE / August 5, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm

5 Aug 22

LOS ANGELES, CA / ACCESSWIRE / August 5, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation ("Apyx" or

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of APYX, NOTV and U

5 Aug 22

NEW YORK, NY / ACCESSWIRE / August 5, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who

APYX SHAREHOLDER ALERT: Jakubowitz Law Reminds Apyx Shareholders of a Lead Plaintiff Deadline of August 5, 2022

5 Aug 22

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm

5 Aug 22

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

12 May 22

9 Aug 22

31 Dec 22

Financial summary

Financial statements Chart APYX financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	26.23M	26.23M	26.23M	26.23M	26.23M	26.23M
Cash burn (monthly)	1.55M	1.11M	1.97M	1.33M	1.51M	1.08M
Cash used (since last report)	6.65M	4.77M	8.46M	5.73M	6.48M	4.63M
Cash remaining	19.58M	21.46M	17.77M	20.5M	19.75M	21.6M
Runway (months of cash)	12.7	19.4	9.0	15.4	13.1	20.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

APYX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Jul 22	Waldman Lawrence	Common Stock	Option exercise	Acquire M	No	No	2.54	24,000	60.96K	37,563
11 Jul 22	Waldman Lawrence	Stock Option (Option to Buy) Common Stock	Option exercise	Dispose M	No	No	2.54	24,000	60.96K	0
11 Jul 22	Moshe Citronowicz	Common Stock	Option exercise	Acquire M	No	No	2.54	30,000	76.2K	456,504
11 Jul 22	Moshe Citronowicz	Stock Option (Option to Buy) Common Stock	Option exercise	Dispose M	No	No	2.54	30,000	76.2K	0
6 Jul 22	Michael Geraghty	Common Stock	Option exercise	Acquire M	No	No	2.54	4,000	10.16K	17,500
6 Jul 22	Michael Geraghty	Stock Option (Option to Buy) Common Stock	Option exercise	Dispose M	No	No	2.54	4,000	10.16K	0
5 Jul 22	Andrew Makrides	Common Stock	Payment of exercise	Dispose F	No	No	6.14	13,583	83.4K	624,389
5 Jul 22	Andrew Makrides	Common Stock	Option exercise	Acquire M	No	No	2.54	30,000	76.2K	637,972
5 Jul 22	Andrew Makrides	Stock Option (Option to Buy) Common Stock	Option exercise	Dispose M	No	No	2.54	30,000	76.2K	0
19 May 22	Waldman Lawrence	Common Stock	Option exercise	Acquire M	No	No	2.79	8,000	22.32K	13,563

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

APYX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Medtronic • Conmed • Medtronic • Inmode

Management Discussion

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.
We are an advanced energy technology company with a passion for elevating people’s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion® and J-Plasma® in surgical markets. We are solely focused on bringing transformative solutions to physicians and their patients. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ablation, alleging, care, carrier, citing, clearance, coagulation, cutting, Drug, economy, evolve, FDA, Food, fully, improper, inflationary, instability, laparoscopic, lapse, lax, letter, loose, matter, minimize, neck, notification, offer, open, optimal, payroll, posted, premarket, relieved, securing, skin, soft, statute, submental, termination, volume

Removed: accurately, adequate, advantage, assessment, auditing, automated, capacity, carryforward, challenging, close, collaborative, confidence, consumer, contact, continuing, cosmetic, curtail, declined, decreased, delaying, depend, difficult, discretionary, disposition, distancing, duration, ease, efficiency, eliminating, emerge, enhance, enterprise, environment, ERP, exposure, extensively, faced, fascial, flow, forego, foreseeable, forming, goal, government, Governmental, half, headcount, high, hiring, hospital, identified, implementation, implemented, implementing, imposing, improved, improvement, improving, inherent, introduction, key, largely, law, limit, liquidity, Maintaining, manage, mind, mitigated, modified, navigate, occurred, operated, optimistic, order, ordered, original, outbreak, paid, permanently, personal, planning, plastic, Policy, pose, positively, potentially, precision, predict, predicted, preemptive, prevent, preventative, prospective, protect, Protecting, protective, public, put, reach, receipt, recovery, reducing, reinstate, release, relief, rely, remain, remediation, remotely, replaced, require, requiring, resource, restrict, sharpen, significantly, site, situation, slower, sluggish, social, source, split, spread, strain, strong, subsequently, summarize, surgeon, surgery, system, target, trauma, Treasury, type, unintended, unknown, unpredictable, virtual, virtually, world, yield

From filing 10-Q 2022 Q1

Financial reports

View all